A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.
about
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquineDifferential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoformsAn investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Single-dose safety, pharmacokinetics, and food effects studies of compound naphthoquine phosphate tablets in healthy volunteers.Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam.
P2860
Q27012807-31F064EE-846E-4C9E-9A70-6A9D352D33EBQ33590189-735EB69C-27BB-4E83-BAF1-BE8A0422EE16Q34694931-D64E75A3-D73A-4ABD-8868-2D0B95E9F4B9Q36254041-31AC435F-6399-48A2-8D44-D8A362C374F1Q36436707-307221AA-6A94-450A-93DA-52B15E50CA78Q37278622-29AF631D-D289-4197-BD2A-0D34DD80C08FQ38028549-D167DCBF-223F-4BD0-B3FD-0F92C2967067Q38057372-3E961F92-D4D5-4039-9D9B-4CA2BF235E51Q39895765-FA8F5842-4DD9-4EB8-9A69-5F59F6BA366CQ44872854-F66EC9FC-00B2-44A0-9758-A366956E1EDBQ45976136-B6362A31-E204-414E-93CE-61A1023F432AQ47890270-EF8560DB-9381-4F10-A68B-A7E80D86C6D8
P2860
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A model based assessment of th ...... ions for combination regimens.
@ast
A model based assessment of th ...... ions for combination regimens.
@en
A model based assessment of th ...... ions for combination regimens.
@nl
type
label
A model based assessment of th ...... ions for combination regimens.
@ast
A model based assessment of th ...... ions for combination regimens.
@en
A model based assessment of th ...... ions for combination regimens.
@nl
prefLabel
A model based assessment of th ...... ions for combination regimens.
@ast
A model based assessment of th ...... ions for combination regimens.
@en
A model based assessment of th ...... ions for combination regimens.
@nl
P2093
P2860
P1476
A model based assessment of th ...... tions for combination regimens
@en
P2093
Doaa A Elsherbiny
Mats O Karlsson
Michael Ashton
Sara A Asimus
P2860
P2888
P304
P356
10.1007/S10928-008-9084-6
P577
2008-03-19T00:00:00Z
P6179
1002194217